$HALO News

Halozyme Therapeutics: Running Through 2027

Halozyme Therapeutics (NASDAQ:HALO) Demonstrates Strong Quality Investing Characteristics Across All Key Metrics

Halozyme Appoints Dannielle Appelhans to its Board of Directors

The Top 5 Analyst Questions From Halozyme Therapeutics’s Q2 Earnings Call

Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics?

Halozyme (HALO) Q2 2026 Earnings Call Transcript

Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why

Is Halozyme Therapeutics (HALO) Stock Outpacing Its Medical Peers This Year?

HALO Q2 Deep Dive: Royalty Diversification and New Pipeline Drive Upgraded Guidance

Halozyme Therapeutics (HALO) Shares Skyrocket, What You Need To Know

Halozyme Therapeutics (HALO) Is Up 24.9% After Raising 2026 Revenue Outlook and Boosting Buybacks

Is Halozyme Therapeutics (HALO) Fairly Valued As Earnings Beat And Guidance Rise?

Halozyme Therapeutics Inc (HALO) (Q2 2026) Earnings Call Highlights: Record Revenue and Royalty ...

Leerink Partners Upgrades Halozyme Therapeutics to Outperform, Raises Price Target to $110

TD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $105

Why Halozyme, An IBD 50 Stock, Just Hit A Record High In Bullish Volume

Halozyme Therapeutics, Inc. Q2 2026 Earnings Call Summary

Citizens Maintains Market Outperform on Halozyme Therapeutics, Raises Price Target to $93

Wells Fargo Maintains Equal-Weight on Halozyme Therapeutics, Raises Price Target to $95

HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $115